Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227331 | 0.94 | TYK2 (0.73) | TYK2JAK2 | |
| SCHEMBL25537143 | 0.91 | TYK2 (0.70) | TYK2JAK2 | |
| SCHEMBL25537145 | 0.88 | TYK2 (0.71) | TYK2JAK2 | |
| SCHEMBL30260243 | 0.85 | TYK2 (0.79) | TYK2 | |
| SCHEMBL25537133 | 0.83 | TYK2 (0.66) | TYK2 | |
| SCHEMBL25537107 | 0.82 | TYK2 (0.70) | TYK2JAK2 | |
| SCHEMBL30227261 | 0.82 | TYK2 (0.68) | TYK2JAK2 | |
| SCHEMBL25536553 | 0.82 | TYK2 (0.93) | TYK2JAK2 | |
| SCHEMBL25537090 | 0.82 | TYK2 (0.67) | TYK2JAK2 | |
| SCHEMBL25537086 | 0.82 | TYK2 (0.67) | TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | TYK2 2/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.